May 9

Past Event

Innovative Technologies and Nonprescription Medications: Addressing Undertreated Diseases and Conditions through Technology Enabled Self-Care

Event Materials

Summary

On May 9, the Engelberg Center for Health Care Reform convened an expert workshop “Innovative Technologies and Nonprescription Medications: Addressing Undertreated Diseases and Conditions through Technology Enabled Self-Care.”

Recognizing the public health impact of undertreatment of common diseases and conditions, the U.S. Food and Drug Administration is exploring how a regulatory expansion of the nonprescription drug class might increase access to important medications and treatments. This initiative is referred to as Nonprescription Safe Use Regulatory Expansion (NSURE).

At this meeting, a wide range of experts and stakeholders explored the use of technologies as a condition to the safe use of medications within a nonprescription setting, discussed perspectives on the role of technology to support the safe and effective use of nonprescription products, and explored the integration of innovative technologies into the health care delivery system.

This expert workshop was the second in a series of meetings that will explore the NSURE initiative. To explore previous discussion regarding the potential role of health care professionals as a condition of safe use within the NSURE paradigm, please visit our expert workshop, “Nonprescription Medications with Conditions of Safe Use as a Novel Solution for Undertreated Diseases or Conditions


Event Agenda

  • Welcome, Introduction and Expert Workshop Objectives

  • Opening Remarks

    • Rachel Sherman

      Director, Office of Medical Policy

      U.S. Food and Drug Administration

  • Role of Technology in Facilitating the Safe and Effective Use of Nonprescription Drugs

    • R. William Soller

      Executive Director and Health Sciences Clinical Professor of Pharmacy

      Center for Consumer Self Care and University of California, San Francisco

  • Session I: Using Innovative Technologies as a Condition of Safe Use

    • Moderator

      mmclellanimage
    • David Schifkovitz

      Vice President, Regulatory Affairs, Wellness Category and North America

      GlaxoSmithKline Consumer Healthcare

    • Erin Oliver

      Director, Regulatory Affairs

      GlaxoSmithKline Consumer Healthcare

    • Lannie Richardson

      Chief Executive Officer

      Central Control, Inc.

    • Malay Gandhi

      Chief Strategy Officer

      Rock Health

    • Donald Reitberg

      Vice President

      Farmacia Electronica, Inc.

  • Session II: Perspectives on the Role of Technologies as a Condition of Safe Use

    • Moderator

      mmclellanimage
    • Julie Aker

      President and Chief Executive Officer

      Concentrics Research, LLC

    • Edwin Hemwall

      Vice President

      Global R&D, Rx-to-OTC Switch and New Opportunity Evaluation, Merck Consumer Care

    • Eric Brass

      Director, Harbor-UCLA Center for Clinical Pharmacology, and Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles

    • Mark Gelbert

      Senior Vice President, Global R&D and Switch

      Pfizer Consumer Healthcare

    • Doris Peter

      Associate Director

      Consumer Reports Health Ratings Center

  • Session III: Integrating Technologies as a Condition of Safe Use into Nonprescription Health Care Delivery Systems

    • Moderator

      mmclellanimage
    • James Owen

      Associate Vice President, Practice and Science Affairs

      American Pharmacists Association

    • Shelly Spiro

      Executive Director

      Pharmacy e-Health Information Technology Collaborative

    • Edward Fotsch

      Chief Executive Officer

      PDR Network

    • Dan Luce

      National Director, Pharmacy Affairs

      Walgreens

  • Closing Remarks

Details

May 9, 2013

9:00 AM - 4:00 PM EDT

The Brookings Institution

1775 Massachusetts Ave., NW

Map

For More Information

Brookings Office of Communications

202.797.6105